Vivesto — Share Issue/Capital Change 2014

Jul 2, 2014

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, HONG KONG, JAPAN ,NEW ZEALAND , SINGAPORE ,SOUTH AFRICA ORTHE UNITED STATES ORIN ANY JURISDICTION IN WHICH THE DISTRIBUTION OF THIS RELEASE WOULD BE UNLAWFUL.

July 2 ,2014

PRESS RELEASE

Oasmia announces launch of private placement of new shares

Oasmia Pharmaceutical AB(publ) ( Oasmia orthe Company )hereby announces the launchofaprivate placement ofnewshares ( NewShares ) through adirected new shareissuetointernational institutional investors andqualified investors inSweden (the Private Placement ).

The price of the New Shares will be determined through an accelerated book building procedure. The bookbuilding will begin onJuly 2 ,2014at 17:40 pmCET.

The Company intends to use the proceeds from the Private Placement tostrengthen the working capital as well as finance the continued operations and further development of additional human and vet erinary products based on the XR -17 technology.

The Private Placement is subject to , inter alia, aresolution by the Board of Directors of Oasmia, pursuant to the authorization granted by the annual general meeting held on September 30, 2013 ,to issue New Shares following thecompletion of the Private Placement book building procedure. Thereason for deviatin gfrom the shareholders preferential rights by conducting a directed new share issue isto broaden the shareholder base and that the costs of the procedure and the timing collectively and with sufficient strength indicate that it is in the Company s and thus the shareholders interest that the issue is made with deviation from the shareholders preferential rights .

Carnegie Investment Bank AB (publ) is acting as financial advisor and sole bookrunner.

The information above has been made public in acco rdance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published onJuly 2 ,2014at 17.30pm CET .

For more information, please contact: Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.widell@oasmia.com

About Oasmia

Oasmia develops new generations of drugs in the field of human and veterinary oncology. The Company's product development aims to develop novel nanoparticle formulations and drugdelivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The Company's product development is based on its proprietary in-house research and company patents. Oasmia's shares, ISIN SE0000722365, are listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

IMPORTANT INFORMATION

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ), Carnegie Investment Bank AB (publ) nor anyone else.